Combined Src/EGFR Inhibition Targets STAT3 Signaling and Induces Stromal Remodeling to Improve Survival in Pancreatic Cancer

Lack of durable response to cytotoxic chemotherapy is a major contributor to the dismal outcomes seen in pancreatic ductal adenocarcinoma (PDAC). Extensive tumor desmoplasia and poor vascular supply are two predominant characteristics which hinder the delivery of chemotherapeutic drugs into PDAC tum...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Molecular cancer research Jg. 18; H. 4; S. 623
Hauptverfasser:	Dosch, Austin R, Dai, Xizi, Reyzer, Michelle L, Mehra, Siddharth, Srinivasan, Supriya, Willobee, Brent A, Kwon, Deukwoo, Kashikar, Nilesh, Caprioli, Richard, Merchant, Nipun B, Nagathihalli, Nagaraj S
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States 01.04.2020
Schlagworte:	Animals Antineoplastic Combined Chemotherapy Protocols - pharmacology Carcinoma, Pancreatic Ductal - drug therapy Carcinoma, Pancreatic Ductal - metabolism Carcinoma, Pancreatic Ductal - pathology Dasatinib - administration & dosage Dasatinib - pharmacology Deoxycytidine - administration & dosage Deoxycytidine - analogs & derivatives Deoxycytidine - pharmacology Disease Models, Animal ErbB Receptors - antagonists & inhibitors ErbB Receptors - metabolism Erlotinib Hydrochloride - administration & dosage Erlotinib Hydrochloride - pharmacology Female Humans Mice Mice, Nude Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - metabolism Pancreatic Neoplasms - pathology Protein Kinase Inhibitors - pharmacology Signal Transduction - drug effects src-Family Kinases - antagonists & inhibitors src-Family Kinases - metabolism STAT3 Transcription Factor - antagonists & inhibitors STAT3 Transcription Factor - metabolism Stromal Cells - drug effects Stromal Cells - metabolism Stromal Cells - pathology Survival Analysis Xenograft Model Antitumor Assays
ISSN:	1557-3125, 1557-3125
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!